Online inquiry

IVTScrip™ mRNA-Anti-CD276, ABBV-155(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ827MR)

This product GTTS-WQ827MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets CD276 gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Chimeric; Humanized
RefSeq NM_001024736.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 80381
UniProt ID Q5ZPR3
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD276, ABBV-155(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ827MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ5127MR IVTScrip™ mRNA-Anti-IL1RAP, CAN-04(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA CAN-04
GTTS-WQ11111MR IVTScrip™ mRNA-Anti-TNFRSF8, MDX-060(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA MDX-060
GTTS-WQ13971MR IVTScrip™ mRNA-Anti-GP, REGN3470-3471-3479(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA REGN3470-3471-3479
GTTS-WQ13653MR IVTScrip™ mRNA-Anti-CD19, RB4v1.2(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA RB4v1.2
GTTS-WQ453MR IVTScrip™ mRNA-Anti-PDGFRA, 3G3(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA 3G3
GTTS-WQ1753MR IVTScrip™ mRNA-Anti-IL2RA, ADCT-301(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA ADCT-301
GTTS-WQ6955MR IVTScrip™ mRNA-Anti-VEGFA, ESBA-1008(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ESBA-1008
GTTS-WQ4307MR IVTScrip™ mRNA-Anti-C1S, BIVV009(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA BIVV009
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW